- Quantitative cancer grading and risk scoring
- Stays focused on practical pathology buyer needs
- Scales to organization-wide healthcare rollouts
PreciseDx
Quantitative AI cancer grading and risk
SF7
SF Score editorial score across features, ease, and value, based on public reviews and product research. Learn more →
Support image analysis for cancer casesCancer pathology and diagnostic programs
Support image analysis for cancer casesCancer pathology and diagnostic programs
Best for
Cancer pathology and diagnostic programs
Pricing
Custom
SoftFinders Score
7 / 10
Overview
What is PreciseDx?
PreciseDx is an AI pathology company for cancer pathology and diagnostic programs, offering quantitative cancer grading and risk tools to support pathology decision-making.
- Workflow focus: The product centers on digital slide workflows, image analysis, and care prioritization rather than autonomous diagnosis, with pathologist review remaining essential.
- Buyer fit: Its clearest fit is organizations seeking quantitative cancer grading and risk scoring within cancer pathology and diagnostic programs.
- Implementation checks: Buyers should confirm lab information system integration, slide scanner compatibility, validation evidence for the tissue types under review, and rollout support.
- Commercial consideration: Its early commercial footprint and narrow scope matter; pricing is sales-led and scoped per buyer.
Overall, PreciseDx is best evaluated for validated pathology workflows where specialist sign-off remains central.
KEY FEATURES
What you get out of the box
Quality Review
Supports quality control across cases
Research Modules
Modules for translational research workflows
Case Sharing
Shares cases across teams for second review
Slide Management
Manages and routes digitized pathology slides
Image Analysis
AI-assisted analysis of tissue images
Biomarker Tools
Tools to explore quantitative biomarkers
USE CASES
Where teams put it to work
Support image analysis for cancer cases
Enable telepathology consult workflows
Manage digital pathology slides centrally
Support biomarker workflows for research
Route cases for specialty review
Prioritize complex pathology cases
Editorial Take
What we like, and what to verify
- Early commercial footprint and narrow scope
- Pathologist sign-off required on every case
- Pricing is sales-led and needs scoping upfront
Screenshots
A look inside
Alternatives
Tools to consider next
Ibex Medical Analytics SF 7.8
Why consider it
AI cancer detection for biopsy slides
Visiopharm SF 7.5
Why consider it
Quantitative digital pathology image analysis
Indica Labs SF 7.6
Why consider it
HALO digital pathology image analysis platform
OptraHEALTH SF 6.8
Why consider it
AI for pathology and genomics knowledge
Aiforia SF 7.4
Why consider it
Cloud deep learning for tissue analysis
Mindpeak SF 7.2
Why consider it
Consistency-focused AI tumor analysis tools
FAQ